NASDAQ:ARGX - argenx Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $101.61 -1.99 (-1.92 %) (As of 12/9/2018 04:00 PM ET)Previous Close$101.61Today's Range$98.79 - $103.3852-Week Range$29.33 - $111.43Volume160,077 shsAverage Volume276,553 shsMarket Capitalization$3.27 billionP/E Ratio-72.58Dividend YieldN/ABeta1.67 ProfileDiscussionAnalyst RatingsChartFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands. Receive ARGX News and Ratings via Email Sign-up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARGX Previous Symbol CUSIPN/A Webwww.argenx.com Phone329-310-3400 Debt Debt-to-Equity RatioN/A Current Ratio13.16 Quick RatioN/A Price-To-Earnings Trailing P/E Ratio-72.58 Forward P/E Ratio-54.05 P/E GrowthN/A Sales & Book Value Annual Sales$44.74 million Price / Sales73.06 Cash FlowN/A Price / Cash FlowN/A Book Value$12.12 per share Price / Book8.38 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees73 Outstanding Shares32,170,000Market Cap$3.27 billion OptionableOptionable argenx (NASDAQ:ARGX) Frequently Asked Questions What is argenx's stock symbol? argenx trades on the NASDAQ under the ticker symbol "ARGX." What price target have analysts set for ARGX? 8 brokerages have issued 1 year target prices for argenx's stock. Their predictions range from $110.00 to $161.00. On average, they anticipate argenx's stock price to reach $140.5714 in the next year. This suggests a possible upside of 38.3% from the stock's current price. View Analyst Price Targets for argenx. What is the consensus analysts' recommendation for argenx? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for argenx. What are Wall Street analysts saying about argenx stock? Here are some recent quotes from research analysts about argenx stock: 1. According to Zacks Investment Research, "argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands. " (11/19/2018) 2. Stifel Nicolaus analysts commented, "We continue to remain positive on the stock at these levels and reiterate our Buy rating. Key Points The AML development landscape is crowded but ARGX-110 stands alone as the only program targeting CD70. Given the poor outcomes in the elderly and high relapse rates in AML, there are many broad and targeted treatments (i.e., specific mutations, immunotherapies) currently in development. KOLs we spoke with indicated there is no silver bullet" when treating the disease and there certainly seems room for new treatments." (10/16/2018) Has argenx been receiving favorable news coverage? News articles about ARGX stock have been trending somewhat positive this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. argenx earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. Who are some of argenx's key competitors? Some companies that are related to argenx include Seattle Genetics (SGEN), Qiagen (QGEN), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), bluebird bio (BLUE), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Repligen (RGEN), China Biologic Products (CBPO), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA) and Crispr Therapeutics (CRSP). Who are argenx's key executives? argenx's management team includes the folowing people: Mr. Tim Van Hauwermeiren, CEO & Exec. Director (Age 46)Mr. Eric Castaldi, Chief Financial Officer (Age 54)Prof. Hans de Haard, Chief Scientific Officer (Age 58)Mr. Dirk Marcel Leon Beeusaert, Gen. Counsel (Age 54)Dr. Torsten Dreier, Chief Devel. Officer (Age 54) When did argenx IPO? (ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are argenx's major shareholders? argenx's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (10.80%), Baker BROS. Advisors LP (3.17%), Redmile Group LLC (3.03%), BB Biotech AG (2.28%), Franklin Resources Inc. (1.87%) and Perceptive Advisors LLC (1.74%). Which institutional investors are selling argenx stock? ARGX stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, VHCP Management II LLC, Renaissance Technologies LLC, Morgan Stanley, Dorsey Wright & Associates, Tekla Capital Management LLC, QVT Financial LP and AWM Investment Company Inc.. Which institutional investors are buying argenx stock? ARGX stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Redmile Group LLC, BB Biotech AG, Jennison Associates LLC, Laurion Capital Management LP, Sphera Funds Management LTD., Franklin Resources Inc. and Jane Street Group LLC. How do I buy shares of argenx? Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is argenx's stock price today? One share of ARGX stock can currently be purchased for approximately $101.61. How big of a company is argenx? argenx has a market capitalization of $3.27 billion and generates $44.74 million in revenue each year. The company earns $-31,730,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. argenx employs 73 workers across the globe. What is argenx's official website? The official website for argenx is http://www.argenx.com. How can I contact argenx? argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The company can be reached via phone at 329-310-3400 or via email at [email protected] MarketBeat Community Rating for argenx (NASDAQ ARGX)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 257 (Vote Outperform)Underperform Votes: 257 (Vote Underperform)Total Votes: 514MarketBeat's community ratings are surveys of what our community members think about argenx and other stocks. Vote "Outperform" if you believe ARGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARGX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/9/2018 by MarketBeat.com StaffFeatured Article: How is the S&P 500 index different from the DJIA?